Principal Consultant
Rohan Patil is one such expert who is helping shape the future of healthcare market insights with his deep industry knowledge and forward-thinking approach. Rohan holds a BSc. in Biotechnology and an MBA in Marketing, a combination that allows him to blend scientific understanding with strategic business acumen. With over 5+ years of experience in the market research industry, Rohan has become a trusted analyst in the healthcare domain, where his insights help clients navigate complex trends and make data-driven decisions.
His expertise spans a range of healthcare sub-sectors, but he is particularly passionate about the medical device industry. As healthcare continues to evolve with technological advancements, he is deeply invested in understanding the innovations shaping the medical devices landscape. He has reviewed and contributed to multiple market reports, where his research has played a pivotal role in identifying emerging opportunities and assessing market risks.
With a keen interest in medical technologies and their transformative impact on patient care, he is always at the forefront of industry developments, ready to provide his clients with the insights they need to stay competitive in an increasingly dynamic market.
His unique combination of biotechnology knowledge, marketing expertise, and market research experience makes him a valuable asset to our team, and his work continues to drive actionable, future-focused strategies in the healthcare sector.
No Media Citations Found.
The blockbuster oncology brands market is forecasted to expand from USD 55.16 billion in 2027 to USD 110.83 billion by 2036, growing at a CAGR of 8.06% from 2027 to 2036.
The global massage equipment market is forecasted to expand from USD 13.27 billion in 2026 to USD 33.41 billion by 2035, growing at a CAGR of 10.80% from 2026 to 2035.
The aromatherapy diffusers market is forecasted to expand from USD 2.48 billion in 2026 to USD 5.23 billion by 2035, growing at a CAGR of 8.65% from 2026 to 2035.
The HbA1c testing devices market is forecasted to expand from USD 1.82 billion in 2026 to USD 4.30 billion by 2035, growing at a CAGR of 10.06% from 2026 to 2035.
The inhaled drugs contract manufacturing market is forecasted to expand from USD 4.30 billion in 2026 to USD 8.62 billion by 2035, growing at a CAGR of 8.04% from 2026 to 2035.
The pneumatic nebulizers market is forecasted to expand from USD 858.18 million in 2026 to USD 1517.72 million by 2035, growing at a CAGR of 6.54% from 2026 to 2035.
The global wound dressing market is forecasted to expand from USD 17.76 billion in 2026 to USD 26.05 billion by 2035, growing at a CAGR of 4.35% from 2026 to 2035.
The U.S. ambulatory surgery center market is forecasted to expand from USD 49.19 billion in 2026 to USD 84.17 billion by 2035, growing at a CAGR of 6.15% from 2026 to 2035.
The molecular nucleic acid testing transfusion medicine market is forecasted to expand from USD 1,053.61 million in 2026 to USD 1,710.27 million by 2035, growing at a CAGR of 5.53% from 2026 to 2035.
The cold and flu supplements market is forecasted to expand from USD 24.65 billion in 2026 to USD 68.51 billion by 2035, growing at a CAGR of 12.03% from 2026 to 2035.
The competent cells market is forecasted to expand from USD 3.55 billion in 2026 to USD 9.13 billion by 2035, growing at a CAGR of 11.05% from 2026 to 2035.
The North America allergy diagnostics market is forecasted to expand from USD 2 billion in 2026 to USD 5.12 billion by 2035, growing at a CAGR of 11.03% from 2026 to 2035. The United States represents the largest national market, supported by established healthcare infrastructure, specialist practices, and laboratory testing capabilities, while Canada and Mexico offer additional growth opportunities through improved diagnostic access and laboratory modernization.
The North America cardiovascular and soft tissue repair patches market is forecasted to expand from USD 2.81 billion in 2026 to USD 5.74 billion by 2035, growing at a CAGR of 8.25% from 2026 to 2035.
The North America enzyme replacement therapy market is forecasted to expand from USD 4.82 billion in 2026 to USD 10.23 billion by 2035, growing at a CAGR of 8.73% from 2026 to 2035.
The North America phenylketonuria treatment market is forecasted to expand from USD 436.00 million in 2026 to USD 946.95 million by 2035, growing at a CAGR of 9% from 2026 to 2035.
The rapid STI testing market is forecasted to expand from USD 1.74 billion in 2026 to USD 3.75 billion by 2035, growing at a CAGR of 8.9% from 2026 to 2035.
The DNA methylation market is forecasted to expand from USD 1.29 billion in 2026 to USD 4.54 billion by 2035, growing at a CAGR of 15.03% from 2026 to 2035.
The dental microscope market is forecasted to expand from USD 344.23 million in 2026 to USD 909.52 million by 2035, growing at a CAGR of 11.4% from 2026 to 2035.
The North America bioprocess analyzers market is forecasted to expand from USD 1.17 billion in 2026 to USD 3.38 billion by 2035 growing at a CAGR of 12.5% from 2026 to 2035. The market is driven by rising production of biologics and heavy investments in research and development.
The radiopharmaceutical preclinical CRO market is forecasted to expand from USD 2.50 billion in 2026 to USD 5.22 billion by 2035, growing at a CAGR of 8.55% from 2026 to 2035.
The North America nucleic acid amplification testing market is forecasted to expand from USD 4.91 billion in 2026 to USD 10.65 billion by 2035, growing at a CAGR of 9% from 2026 to 2035.
The North America cardiovascular repair and reconstruction devices market is forecasted to expand from USD 2.02 billion in 2026 to USD 3.50 billion by 2035, growing at a CAGR of 6.3% from 2026 to 2035. The market is driven by well-established reimbursement frameworks and supportive regulatory pathways from the U.S. FDA, along with substantial healthcare spending, funding fast market access and high-tech adoption.
The North America multi-modality aesthetic platforms market is forecasted to expand from USD 235.10 million in 2026 to USD 525.56 million by 2035, growing at a CAGR of 9.35% from 2026 to 2035.
The North America hereditary testing market is expected to grow at a CAGR of 15.02% during the forecast period, reaching USD 24.23 billion in 2035. The development of whole-genome sequencing and whole-exome sequencing approaches, growing awareness about the influence of genes, rapid advancement in infrastructure in developing markets, and the modernizing distribution environment are benefiting the market. Deepa Pandey, our Senior Research Analyst, has over 5 years of experience in the healthcare and medicine industry. According to her, the development of novel non-invasive sample collection approaches and the transition from target panels to whole-genome analysis are improving patient convenience and facilitating comprehensive genomic analysis, respectively.
Healthcare systems are becoming more structured and personalized in the treatment of bladder control disorders across Europe. Traditional urinary incontinence therapeutics are moving into the spotlight. Urinary incontinence is associated with diminished quality of life. There is an ever-increasing need for therapeutic options that will help this population achieve better outcomes, especially in aging. Deepa Pandey brings over 5 years of experience in market analysis in healthcare and life science. She notes a transformational shift in the urology care landscape in Europe, where patient awareness and the innovation of pharmaceutical play a key role in shaping practice patterns.
The surging respiratory and gastrointestinal infection cases have increased the need for rapid multi-pathogen testing from a single sample and reduced diagnostic turnaround times in critical care. Deepa Pandey has more than 5 years of experience focusing on the healthcare and medicine sector. The market is estimated at USD 94.39 million in 2026, expanding at a CAGR of 5.95% during the forecast period from 2026 to 2035. The market is driven by expanding private and public healthcare diagnostic investments, adoption of cartridge-based point-of-care testing platforms, and major global assay launches entering the Indian market.
The computerized physician order entry market is forecasted to expand from USD 2.39 billion in 2026 to USD 4.16 billion by 2035, growing at a CAGR of 6.35% from 2026 to 2035. Thus, eliminating the manual ordering process. Deepa Pandey has more than 5 years of healthcare & life sciences market analysis experience. She observes a massive transformation in the field of healthcare digitization. CPOE systems enable physicians to electronically enter clinical orders such as medication, laboratory, imaging, and other orders, and link these orders with EHRs and clinical decision-support systems. On the other hand, Asia-Pacific is regaining its momentum in connection with the digitalization of hospitals and also the increasing investments in healthcare information systems.
Increased participation in high-impact sports, fitness activities, and recreational athletics across all age groups has contributed to a surge in lower-extremity sprains, tears, and fractures. Meanwhile, the introduction of lightweight implants, bioabsorbable fixation materials, 3D-printed custom devices, and digital or robotic surgical support improves patient outcomes and boosts adoption. Deepa Pandey has more than 5 years of experience focusing on the healthcare and medicine sector. Advancements in minimally invasive surgical methods, 3D-printed patient-matched implants, and bioabsorbable fixation devices improve healing results and shorten recovery times. The market is estimated at USD 2.30 billion in 2026, expanding at a CAGR of 6.85% during the forecast period from 2026 to 2035. The market is driven by an increase in high-impact sports activities, recreational fitness, and road traffic accidents worldwide, which raise the frequency of lower extremity fractures and ankle trauma.
The anti-obesity medication market is forecasted to expand from USD 26.19 billion in 2026 to USD 318.63 billion by 2035, growing at a CAGR of 32% from 2026 to 2035. The development and approval of dual GIP/GLP-1 receptor agonists, adoption of novel indications for obesity medications, and innovation in oral and next-generation incretin products are benefiting the market. Deepa Pandey, our Senior Research Analyst, has over 5 years of experience in the healthcare and medicine industry. According to her, the widening range of applications and the recognition of integrated treatments that help in weight reduction alongside addressing other obesity-related conditions are driving the market growth.
The preclinical bioanalytical testing services market is forecasted to expand from USD 1.31 billion in 2026 to USD 3.29 billion by 2035, growing at a CAGR of 10.8% from 2026 to 2035. Meanwhile, evolving regulatory standards require precise pharmacokinetic (PK), toxicokinetic (TK), and even biomarker validation data before human trials. Deepa Pandey has more than 5 years of experience focusing on the healthcare and medicine sector. Automated robotic liquid handlers and integrated sample-preparation systems standardize repetitive tasks like pipetting, dilution, and plate preparation, decreasing human error and boosting daily throughput. The market is estimated at USD 1.31 billion in 2026, expanding at a CAGR of 10.80% by 2035. Agencies such as the U.S. FDA and the European Medicines Agency (EMA) need rigorous, precise pharmacokinetic and toxicokinetic data during preclinical evaluations, thus prompting pharmaceutical sponsors to partner with specialized laboratories.
The extractable and leachable (E&L) testing services market is forecasted to expand from USD 1,255.57 million in 2026 to USD 3,694.41 million by 2035, growing at a CAGR of 12.74% from 2026 to 2035. The development of advanced leachables and extractables analysis methodologies is facilitating the analysis of complicated materials and the detection of impurities at very low concentrations, which aligns with the current needs of the clients. Deepa Pandey, our Senior Research Analyst, who has over 5 years of experience in the healthcare and medicine industry, identified that the widening range of applications and advancements in chemistries and methodologies for identifying compounds and assessing the risks they pose to patients is benefiting the market.
Increasing regulatory scrutiny and chemical development pipelines, environmental concerns surrounding industrial substances, and stronger requirements for safety evaluation are reshaping testing practices in the sector. Deepa Pandey has more than 5 years' healthcare & life sciences market analysis experience and observes a massive transformation in the field of animal testing & ecotoxicology testing.
The vascular patches market is forecasted to expand from USD 583.92 million in 2026 to USD 1,051.15 million by 2035, growing at a CAGR of 6.75% from 2026 to 2035. Meanwhile, the growing utilization in ambulatory surgical centers (ASCs) is driven by outpatient procedures becoming more cost-effective. Deepa Pandey has more than 5 years of experience focusing on the healthcare and medicine sector. Manufacturers are increasingly investing in advanced platforms, which include nanotechnology, antimicrobial agent incorporation to prevent post-surgery infections, and even tissue-engineered or 3D-printed patient-specific patches; the market is estimated at USD 547 million in 2025, expanding at a CAGR of 8.02% by 2035. The market is driven by outpatient procedures and treatments, and ASC volumes are growing rapidly as healthcare professionals seek to lower costs and work with value-based reimbursement models.
The pharma 5.0 market is forecasted to expand from USD 9.83 billion in 2026 to USD 59.14 billion by 2035, growing at a CAGR of 22.07% from 2026 to 2035. Deepa Pandey has more than 5 years of experience in healthcare analytics and explains that the time for technology-driven transformation in the pharmaceutical industry has arrived. The global pharma 5.0 market size is expected to grow at a CAGR of 22.07% during the forecast period.
The antihyperlipidemic market is forecasted to expand from USD 15.87 billion in 2026 to USD 26.00 billion by 2035, growing at a CAGR of 5.64% from 2026 to 2035. The development of innovative combination therapies and targeted non-statin treatments, an effective and timely diagnostic ecosystem, and the development of residual risk detection technologies are propelling the market. Deepa Pandey, our Senior Research Analyst, has over 5 years of experience in the healthcare and medicine industry. She has conducted thorough research on factors affecting the adoption of conventional statin treatments, future opportunities, regulatory updates, and the potential for novel innovative therapies to compete in the market through a wider scope and patient convenience.
The transcutaneous electrical nerve stimulation (TENS) market is forecasted to expand from USD 408.68 million in 2026 to USD 886.13 million by 2035, growing at a CAGR of 8.98% from 2026 to 2035. The surging demand for compact, wireless, smartphone-connected TENS units that enable users to customize therapy discreetly on the go is the driving factor for the market. Deepa Pandey, who has more than 5 years of experience in healthcare research, has found that the rising prevalence of chronic musculoskeletal conditions and an aging global demographic drive market growth. The market is divided into single-channel and dual-channel devices used for back pain, sports injuries, arthritis, and postoperative recovery across home care and clinical settings.
The semaglutide market is forecasted to expand from USD 34.03 billion in 2026 to USD 90.27 billion by 2035, growing at a CAGR of 11.45% from 2026 to 2035. Regulatory approval of innovative medications for metabolic conditions, effective formulations, and a rapidly improving distribution ecosystem are benefiting the market. Deepa Pandey, our Senior Research Analyst, has over 5 years of experience in the healthcare and medicine industry. According to her, the widening range of applications and advancements in the means of administration are boosting the semaglutide industry. The rising prevalence of diabetes, obesity, and cardiovascular conditions due to modern lifestyle and diet issues, and the swift development of healthcare infrastructure in middle-income countries are propelling the market growth.
The medical collagen market is forecasted to expand from USD 362.10 million in 2026 to USD 638.23 million by 2035, growing at a CAGR of 6.5% from 2026 to 2035. Medical collagen is becoming increasingly significant for regenerative medicine and advanced healthcare applications. According to our primary researcher, Deepa Pandey, the rising demand for wound healing products, tissue engineering solutions, bone graft substitutes, and collagen-based surgical materials is bolstering growth in the industry.
Deepa Pandey has more than 5 years of experience focusing on the healthcare and medicine sector. She believes the rising trend of changing consumer preferences and ongoing pharmaceutical advancements is transforming the acetaminophen industry. The acetaminophen market is forecasted to expand from USD 10.63 billion in 2026 to USD 15.73 billion by 2035, growing at a CAGR of 4.45% from 2026 to 2035. The widespread availability of generic formulations and combination medicines, pediatric formulations, and convenient dosage forms is also helping the market. A rise in the incidence of diseases linked to pain and fever, along with growing self-medication and greater access to healthcare in developing economies, is helping market growth. The acetaminophen market is expanding at a CAGR of 4.45% from 2026 to 2035.
Deepa Pandey has more than 5 years of experience in the consumer products and emerging tobacco alternatives space. She states that the nicotine pouches category is at a new level of growth. The nicotine pouches market is forecasted to expand from USD 8.81 billion in 2026 to USD 65.55 billion by 2035, growing at a CAGR of 24.98% from 2026 to 2035. Increased consumer demand for smoke-free nicotine consumption and products continue to innovate with new flavor options, new pouch sizes, and new nicotine levels. These strengths have allowed manufacturers to significantly diversify their product offering and geographical presence.
Deepa Pandey has more than 5 years of experience in the healthcare and wellness industry. She states that the kratom market is being taken in a more commercial direction. The demand for plant-based products, traditional botanicals, and alternative wellness products is also on the rise. Manufacturers are more focused on standardized products, quality assurance, product testing, and differentiated formulations. The kratom market is forecasted to expand from USD 4.42 billion in 2026 to USD 14.54 billion by 2035, growing at a CAGR of 14.15% from 2026 to 2035.
Encompassing blood filtration and blood purification, the field has grown more advanced in clinical settings. Deepa Pandey has more than 5 years of experience in medical device & blood-processing technology for healthcare analysis. She analysed a wide range of aspects, from patient experiences and the spread of extracorporeal purification technology to the ongoing progress in purification membranes and system components.
With more than five years of healthcare and medical device market analysis experience, Deepa Pandey believes the medical device contract sales organizations market is now in a new phase. Contract sales organisations are becoming an increasingly important part of traditional sales organisations. As manufacturers adopt more flexible commercial models, pressure to manage selling costs grows, and there is an increasing need for specialized sales skills.
Deepa Pandey has more than 5 years of experience in medical device and chronic care healthcare analysis. She believes that the ostomy care market is transitioning to a more patient-centric phase. As colorectal cancer is becoming more prevalent in society, patients are becoming more aware of effective ostomy care. With innovations in pouching technology and skin protection products, patients are having more options that will allow them to enjoy more comfortable and reliable long-term care. The global ostomy care market was valued at USD 4.01 billion in 2026 and is growing at a CAGR of 4.46% over the forecast period. Additionally, the number of elderly citizens and the increasing incidence of colorectal and gastrointestinal diseases are anticipated to continue to be the drivers of market growth.
Payment integrity is moving closer to the claims-adjudication process as payers seek to identify payment errors earlier in the cycle. Claims-editing engines, clinical rules, provider-level analytics, and machine learning can flag duplicate claims, coding inconsistencies, unsupported services, unusual provider activity, and potential fraud before or shortly after payment. This does not eliminate retrospective recovery; it expands payment integrity from recovering losses after payment to preventing or reducing avoidable leakage earlier. The market was valued at USD 18.33 billion in 2026 and is projected to grow at a 14.21% CAGR through 2035.
According to Deepa Pandey, who has more than 5 years' experience in healthcare research analysis. AI agents are widely used for traditional transcription services. They are replacing manual data entry and making it more efficient by minimizing errors. The need for technology that makes clinical daily tasks more efficient is driving the growth in the global AI agents for clinical documentation market. The global AI agents for clinical documentation market is projected to experience robust growth over the forecast period, as the increasing burden of documentation for physicians. These factors contribute to improved clinical workflow efficiency and are expected to support market growth. Deepa Pandey believes that the shift from passive AI transcription to agentic clinical documentation is a significant market transition.
Deepa Pandey has over 5 years of experience in healthcare analysis of medical devices and renal care and notes that peritoneal dialysis is taking a new direction. With a more technology-driven approach, more patients are choosing to treat at home, evolving preferences for APD vs. CAPD, and a growing demand for connected dialysis options. The global peritoneal dialysis market size was valued at USD 10.68 billion in 2026 and is estimated to grow to USD 18.12 billion by 2035, growing at a CAGR of 6.05% during the forecast period. Deepa Pandey identifies the transition from continuous to automated peritoneal dialysis, increasing home dialysis uptake in the wake of reimbursement reform. Further, a growing population of chronic kidney disease (CKD) patients in Asia-Pacific is the strongest contributor to that growth.
With over 5 years of pharmaceutical manufacturing and sterile injectable research experience into the trends of CDMO capacity, Deepa Pandey believes that the market is poised to experience a real decade of capital investment instead of an incremental one. The fill finished manufacturing market for the global fill is estimated at USD 21.82 billion in 2026 and is expected to grow at 9.10% CAGR during the forecast period to reach approximately USD 47.8 billion by 2035. The commercialization of cell and gene therapies, the transition to prefilled syringes and self-administered injectables, and capacity investment in multi-billion-dollar deals like those of Novo Nordisk, Samsung Biologics, and Lonza all point to that growth, interpreted in her analysis.
The global exosome drug delivery services market size is predicted to increase from USD 5.70 billion in 2026 to approximately USD 24.33 billion by 2035, expanding at a CAGR of 17.50% from 2026 to 2035.
The Middle East Cyclotron-Produced Radioisotopes Market demonstrated a strong market presence in 2026 and is projected to maintain steady momentum from 2026 through 2035, supported by rising demand, expanding applications, and continued industry adoption. The market is witnessing steady growth, driven by the increasing adoption of positron emission tomography (PET)-based molecular imaging, expanding cancer incidence across the Middle East, rising investments in nuclear medicine infrastructure, and growing government initiatives to establish domestic radioisotope production capabilities. The expansion of cyclotron installations, increasing demand for precision diagnostics and theranostic radiopharmaceuticals, and efforts to reduce dependence on imported short-lived radioisotopes are further supporting market growth.
The market is expected to witness significant growth, driven by increasing government interest in nuclear energy diversification, rising demand for a secure and uninterrupted supply of medical radioisotopes, advancements in Small Modular Reactor (SMR) technologies, and the growing adoption of targeted radionuclide therapies. Furthermore, increasing investments in nuclear infrastructure, localization of radioisotope production, and the development of next-generation reactor technologies are anticipated to accelerate the commercialization of SMR-based radioisotope production across the Middle East.
The global AI in cancer immunotherapy drugs market size is predicted to increase from USD 3.52 billion in 2026 to approximately USD 27.79 billion by 2035, expanding at a CAGR of 25.80% from 2026 to 2035.
The global cardiac marker testing market is predicted to increase from USD 6.01 billion in 2026 to approximately USD 14.59 billion by 2035, expanding at a CAGR of 10.35% from 2026 to 2035.
The global adhesion barrier market size is predicted to increase from USD 846.60 million in 2026 to approximately USD 1,596.15 million by 2035, expanding at a CAGR of 7.30% from 2026 to 2035.
The global precision biotics market size is predicted to increase from USD 5.56 billion in 2026 to approximately USD 17.46 billion by 2035, expanding at a CAGR of 13.55% from 2026 to 2035.
The global dental crown remover market size is predicted to increase from USD 330.41 million in 2026 to approximately USD 553.50 million by 2035, expanding at a CAGR of 5.90% from 2026 to 2035. The market growth is attributed to increasing restorative dental procedures and continuous advancements in precision crown removal technologies.
The global GLP-1 market is predicted to increase from USD 66.46 billion in 2026 to approximately USD 212.73 billion by 2035, expanding at a CAGR of 13.80% from 2026 to 2035. The market is driven by the expanding clinical indication of these therapies, which are now evolving from handling Type 2 diabetes to long-term chronic weight management and even cardiovascular risk reduction.
The global 3T MRI system market size is predicted to increase from USD 3.65 billion in 2026 to approximately USD 6.63 billion by 2035, expanding at a CAGR of 6.85% from 2026 to 2035. The market is driven by the increasing prevalence of neurological disorders, like Alzheimer's and Parkinson's, and complex cancers, which need the superior spatial resolution and tissue contrast offered by 3T systems for early, highly accurate diagnosis.
The global electric breast pumps market size is predicted to increase from USD 1.16 billion in 2026 to approximately USD 2.21 billion by 2035, expanding at a CAGR of 7.40% from 2026 to 2035. The market is driven by growing participation of women in the worldwide workforce, which is accelerating the need for efficient, portable, and time-saving pumping solutions.
The global hemodialysis and peritoneal dialysis market size is predicted to increase from USD 120.16 billion in 2026 to approximately USD 219.05 billion by 2035, expanding at a CAGR of 6.90% from 2026 to 2035. The market is driven by the increasing global prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD). This is directly fueled by an aging demographic and even rising rates of lifestyle-related conditions such as diabetes and hypertension.
The global CNS clinical trials market size is predicted to increase from USD 9.33 billion in 2026 to approximately USD 18.49 billion by 2035, expanding at a CAGR of 7.90% from 2026 to 2035. The market is driven by the rising global prevalence of neurodegenerative diseases, like Alzheimer's, Parkinson's, and Huntington's, combined with an aging global population.
The global decentralized clinical trials in neurology market size is predicted to increase from USD 1.71 billion in 2026 to approximately USD 6.38 billion by 2035, expanding at a CAGR of 15.80% from 2026 to 2035. The increasing prevalence of neurological diseases and clinical trial activities are key growth factors for the market.
The global sevoflurane market size is predicted to increase from USD 1.22 billion in 2026 to approximately USD 2.02 billion by 2035, expanding at a CAGR of 5.80% from 2026 to 2035. Growing surgical volumes, increasing healthcare expenditure, expansion of ambulatory surgical centers, rising prevalence of chronic diseases requiring surgical intervention, and advancements in anesthesia delivery systems are driving market growth.
The global brain health supplements and therapeutics market size is anticipated to increase from USD 20.42 billion in 2026 to approximately USD 47.37 billion by 2035, expanding at a CAGR of 9.80% from 2026 to 2035. The market is driven by the rapid global aging population, which brings a rising prevalence of age-related cognitive and neurodegenerative diseases such as Alzheimer's and dementia.
The global cognitive assessment and brain health market size is predicted to increase from USD 10.51 billion in 2026 to approximately USD 28.69 billion by 2035, expanding at a CAGR of 11.80% from 2026 to 2035. Rising neurological disease prevalence, growing awareness, and improved diagnosis are key factors driving growth in the market.
The US pathology laboratories market size is predicted to increase from USD 112.33 billion in 2026 to approximately USD 229.75 billion by 2035, expanding at a CAGR of 7.42% from 2026 to 2035. The market is growing due to strategic partnerships between hospitals and laboratory service providers and growing demand for oncology, neurology, autoimmune disease, and women's health testing.
The US anesthesia devices market size is predicted to increase from USD 7.41 billion in 2026 to approximately USD 14.20 billion by 2035, expanding at a CAGR of 7.44% from 2026 to 2035. The market growth is attributed to increasing surgical procedure volumes, expanding ambulatory care infrastructure, and continuous advancements in anesthesia delivery and patient monitoring technologies.
The US peptide therapeutics market size is predicted to increase from USD 22.63 billion in 2026 to approximately USD 34.98 billion by 2035, expanding at a CAGR of 5.12% from 2026 to 2035. The market growth is attributed to rising obesity and diabetes prevalence, expanding peptide drug innovation, increasing GLP-1 therapy adoption, and growing investments in advanced peptide manufacturing technologies.
The US pharmaceutical stability and storage services market size is predicted to increase from USD 1.76 billion in 2026 to approximately USD 2.92 billion by 2035, expanding at a CAGR of 5.81% from 2026 to 2035. The market is experiencing robust growth, driven by rising biologics and specialty drug development, expanding clinical trial activities, and stringent regulatory requirements for product quality and long-term stability testing throughout the drug development and commercialization lifecycle.
The US direct-to-consumer laboratory testing market size is predicted to increase from USD 1.34 billion in 2026 to approximately USD 2.92 billion by 2035, expanding at a CAGR of 9.03% from 2026 to 2035. The market growth is attributed to rising demand for preventive healthcare, personalized diagnostics, at-home testing solutions, and increasing adoption of digital laboratory platforms.
The US regulatory affairs market size is predicted to increase from USD 4.64 billion in 2026 to approximately USD 9.02 billion by 2035, expanding at a CAGR of 7.66% from 2026 to 2035. The market growth is attributed to increasing regulatory complexity, expanding healthcare innovation, rising FDA submission volumes, and growing adoption of AI-enabled regulatory technologies.
The US orthodontics market size is predicted to increase from USD 7.87 billion in 2026 to approximately USD 20.63 billion by 2035, expanding at a CAGR of 11.40% from 2026 to 2035. The market is driven by rising demand for clear aligners and cosmetic dental procedures, increasing awareness of oral health, technological advancements in digital orthodontics, and escalating insurance coverage.
The US controlled substance market size is predicted to increase from USD 32.74 billion in 2026 to approximately USD 52.11 billion by 2035, expanding at a CAGR of 5.70% from 2026 to 2035. The market growth is attributed to increasing prescription demand for pain management, ADHD, seizure disorders, and addiction treatment, supported by expanding healthcare access and stringent controlled-substance monitoring systems.
The US glioblastoma multiforme treatment market size is predicted to increase from USD 850.30 million in 2026 to approximately USD 1,634.84 million by 2035, expanding at a CAGR of 7.55% from 2026 to 2035. The market growth is attributed to the rising incidence of glioblastoma, expanding clinical research activity, and continuous advancements in precision oncology and targeted treatment technologies.
The global tylosin market size is predicted to increase from USD 969 million in 2026 to approximately USD 1,532 million by 2035, expanding at a CAGR of 5.30% from 2026 to 2035. The market is rapidly expanding due to the increasing demand for protein-rich foods, commercial poultry and swine farming, and mandatory rules to prevent bacterial infections in livestock amid rising meat consumption.
The US medical devices market size is predicted to increase from USD 203.06 billion in 2026 to approximately USD 346.19 billion by 2035, expanding at a CAGR of 6.20% from 2026 to 2035. The market growth is attributed to increasing adoption of advanced medical technologies, expanding healthcare infrastructure, and continuous innovation in diagnostic and therapeutic devices.
The US rehabilitation equipment market is predicted to increase from USD 5.48 billion in 2026 to approximately USD 9.07 billion by 2035, expanding at a CAGR of 5.74% from 2026 to 2035. The market growth is attributed to increasing disability prevalence, rising rehabilitation service utilization, expanding geriatric populations, and growing adoption of advanced mobility and assistive rehabilitation technologies.
The US AI in medical imaging market size is predicted to increase from USD 909.63 billion in 2026 to approximately USD 7,640.97 billion by 2035, expanding at a CAGR of 26.71% from 2026 to 2035. The market growth is attributed to rising adoption of AI-powered diagnostic tools, increasing imaging volumes, and expanding FDA-cleared imaging applications across healthcare systems.
The global implantable sensor orthopedic market size is predicted to increase from USD 3.06 billion in 2026 to approximately USD 13.17 billion by 2035, expanding at a CAGR of 17.04% from 2026 to 2035. The increasing incidence of accidents and chronic diseases, along with further advancements in healthcare devices, support market growth.
The global ceftriaxone sodium market size is predicted to increase from USD 2.99 billion in 2026 to approximately USD 4.52 billion by 2035, expanding at a CAGR of 4.80% from 2026 to 2035. The market is driven by the increasing global prevalence of severe bacterial infections.
The US nitrile gloves market size is predicted to increase from USD 7.38 billion in 2026 to approximately USD 14.22 billion by 2035, expanding at a CAGR of 7.53% from 2026 to 2035. The market growth is attributed to increasing healthcare safety requirements, expanding industrial protection standards, and rising demand for contamination control across pharmaceutical, food processing, and advanced manufacturing industries.
The global US gynecological devices market size is predicted to increase from USD 4.51 billion in 2026 to approximately USD 9.10 billion by 2035, expanding at a CAGR of 8.12% from 2026 to 2035. The increasing adoption of minimally invasive procedures by healthcare professionals to treat women and technological advancements in hydrothermal ablation devices drive the market growth.
The US cell and gene therapy market size is predicted to increase from USD 4.74 billion in 2026 to approximately USD 20.00 billion by 2035, expanding at a CAGR of 17.21% from 2026 to 2035. The market is experiencing steady growth due to the rising investments in oncology and rare genetic diseases, strategic alliances between industry players and academic institutions, and personalized solutions for common and rare diseases.
The global neuropharmacology market size is predicted to increase from USD 168.29 billion in 2026 to approximately USD 311.78 billion by 2035, expanding at a CAGR of 7.20% from 2026 to 2035. The increasing prevalence of neurological diseases, advances in research, and the growing number of clinical trials are key factors driving market growth.
The US pharmaceutical excipients market size is predicted to increase from USD 3.28 billion in 2026 to approximately USD 5.58 billion by 2035, expanding at a CAGR of 6.12% from 2026 to 2035. The market growth is attributed to rising demand for biologics, specialty drugs, and advanced pharmaceutical formulations requiring high-performance excipients.
The US stroke diagnostic and therapeutic market is predicted to increase from USD 6.97 billion in 2026 to approximately USD 15.04 billion by 2035, expanding at a CAGR of 8.92% from 2026 to 2035. The market is driven by the increasing adoption of advanced imaging technologies, an escalating incidence of stroke due to aging, and increasing industrial development.
The US skin repair market size is predicted to increase from USD 25.98 billion in 2026 to approximately USD 47.43 billion by 2035, expanding at a CAGR of 6.84% from 2026 to 2035. The growing focus on reducing skin problems of the people and the surging deployment of advanced technologies in the cosmetics industry drive the market expansion.
The US dermatology market size is predicted to increase from USD 512.05 million in 2026 to approximately USD 973.78 million by 2035, expanding at a CAGR of 7.38% from 2026 to 2035. The market is driven by the increasing prevalence of chronic skin diseases, growing awareness of skin health, and rising demand for minimally invasive cosmetic procedures.
The U.S. cosmeceuticals market size is predicted to increase from USD 17.58 billion in 2026 to approximately USD 38.27 billion by 2035, expanding at a CAGR of 8.98% from 2026 to 2035. The market growth is attributed to the rising demand for science-backed skincare, biotechnology-derived ingredients, and personalized beauty solutions.
The US pharmacy automation market size is predicted to increase from USD 2.19 billion in 2026 to approximately USD 5.22 billion by 2035, expanding at a CAGR of 10.12% from 2026 to 2035. The market growth is attributed to the rising adoption of intelligent medication management systems, expanding digital healthcare infrastructure, and increasing demand for accurate, high-volume prescription dispensing.
The US electron microscopy market size is predicted to increase from USD 1.50 billion in 2026 to approximately USD 2.99 billion by 2035, expanding at a CAGR of 7.88% from 2026 to 2035. The market growth is attributed to rising semiconductor investments, expanding nanotechnology research, and increasing demand for atomic-scale characterization capabilities.
The US brachytherapy market size is predicted to increase from USD 370.79 billion in 2026 to approximately USD 699.86 million by 2035, expanding at a CAGR of 7.32% from 2026 to 2035. The market growth is attributed to rising cancer incidence, increasing adoption of precision radiation therapies, and continuous advancements in brachytherapy technologies.
The global remote neurological monitoring market size is predicted to increase from USD 2.81 billion in 2026 to approximately USD 9.69 billion by 2035, expanding at a CAGR of 14.80% from 2026 to 2035. The market is driven by the rising integration of artificial intelligence (AI) and cloud analytics, which enable real-time predictive care and also early detection of neurodegenerative diseases outside traditional hospital settings.
The US active pharmaceutical ingredients market size is predicted to increase from USD 44.46 billion in 2026 to approximately USD 79.80 billion by 2035, expanding at a CAGR of 6.69% from 2026 to 2035. The increasing demand for precision medicines, along with the technological advancements in the biopharma industry, has driven the market.
The US CAR T-cell therapy market size is predicted to increase from USD 2,684.84 million in 2026 to approximately USD 11,510.04 million by 2035, expanding at a CAGR of 17.47% from 2026 to 2035. The market is expanding rapidly due to increasing cancer incidence, growing adoption of personalized medicine, and continuous FDA approvals for new indications and products.
The US infant incubator market size is predicted to increase from USD 224.31 million in 2026 to approximately USD 442.25 million by 2035, expanding at a CAGR of 7.79% from 2026 to 2035. The market is driven by the rising prevalence of preterm births, increasing neonatal intensive care unit (NICU) admissions, advancements in neonatal care technologies, expanding healthcare infrastructure, and growing government investments in maternal and infant healthcare services.
The global CNS drug discovery market size is predicted to increase from USD 10.86 billion in 2026 to approximately USD 27.55 billion by 2035, expanding at a CAGR of 10.90% from 2026 to 2035. The rising prevalence of CNS disorders, the integration of AI and ML in drug discovery, and increased government support for clinical trials and funding are significant factors driving market growth.
The US pharmaceutical water market size is predicted to increase from USD 8.66 billion in 2026 to approximately USD 17.97 billion by 2035, expanding at a CAGR of 8.65% from 2026 to 2035. The market is witnessing substantial growth due to the escalating burden of chronic diseases and the surging demand for high-quality biologics and sterile injectables. This expansion is supported by stringent FDA sterility standards and rapid advancements in water purification technologies, spurring massive investments in pharmaceutical manufacturing infrastructure.
The US biosensors market size is predicted to increase from USD 11.69 billion in 2026 to approximately USD 20.42 billion by 2035, expanding at a CAGR of 6.51% from 2026 to 2035. The market is driven by the rising prevalence of chronic diseases, increasing demand for point-of-care testing, and advancements in wearable healthcare technologies.
The US bone grafts and substitutes market size is predicted to increase from USD 1.38 billion in 2026 to approximately USD 2.25 billion by 2035, expanding at a CAGR of 5.56% from 2026 to 2035. Market growth is driven by the increasing prevalence of orthopedic disorders, rising sports injuries, a growing aging population, and expanding demand for minimally invasive surgical procedures.